Dr. Kuo on PSMA-PET imaging biomarker research

Phillip Kuo, MD, PhD, Departments of Medical Imaging, Medicine, and Biomedical Engineering, University of Arizona, discusses the abstract, “[68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: A VISION substudy,” which was presented at the 2022 ASCO Annual Meeting.

The post-hoc exploratory analysis specifically showed that a higher whole-body SUVmean was strongly associated with improved long-term clinical outcomes among men in the VISION trial with PSMA-positive mCRPC on 68Ga-PSMA-11 PET/CT treated with 177Lu-PSMA-617.

Related Videos
Benjamin Lowentritt, MD, FACS, in an interview with Urology Times
Dr. Goldfischer in an interview during the LUGPA Annual Meeting
Related Content
© 2023 MJH Life Sciences

All rights reserved.